Appello Pharmaceuticals nets $10.5 million in Series A funding for Parkinson’s drugs
The company will use the funding to develop mGlu4 PAMs licensed from Vanderbilt University.
Prexton Pharmaceuticals
The company will use the funding to develop mGlu4 PAMs licensed from Vanderbilt University.